Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Celanese Q4 Earnings

Celanese (NYSE:CE) reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:30 PM. Here’s what investors…
byBenzinga Insights
February 20, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Celanese (NYSE:CE) reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:30 PM.

Here’s what investors need to know about the announcement.

Earnings

Celanese missed estimated earnings by 3.03%, reporting an EPS of $2.24 versus an estimate of $2.31.

Revenue was up $221.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.27 which was followed by a 2.88% drop in the share price the next day.

Here’s a look at Celanese’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 2.23 2.46 1.64 1.66
EPS Actual 2.50 2.17 2.01 1.44
Revenue Estimate 2.77B 2.84B 2.86B 2.40B
Revenue Actual 2.72B 2.79B 2.85B 2.35B

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

Celanese management provided guidance for Q1 2024, expecting earnings between $1.75 and $2.0 per share.

To track all earnings releases for Celanese visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CBD Giant’s Challenging Year: Q4 Net Sales Slide By 27% But Net Loss Narrows 67% YoY

By Jelena Martinovic
December 26, 7:05 PM
cbdMD reported a 27% year-over-year drop in net sales for the fourth quarter of 2023, totaling $5.7 million. The company attributed the decline to industry trends, reduced marketing spend, and lower wholesale pricing for its new high-strength products. For the full fiscal year 2023, net sales reached $24.2 million, down from $35.4 million in the previous year. Gross profit for the year was approximately $15 million, a decrease from $22.3 million in fiscal 2022. The company reported a net loss of about $23 million, compared to $70 million in 2022. Operating expenses fell to $24.2 million from $40 million in the prior year. cbdMD's working capital on September 30, 2023, was $3.4 million, down from $10.7 million on the same date in 2022. The company also launched its hempMD and ATRx brands in 2023, expanding its product channels into Amazon and other consumer products channels.

YCBD